Prostate cancer is the most common cancer in South African men. It spans an enormous range of clinical urgency — from slow-growing tumours managed with monitoring alone, to aggressive metastatic disease requiring expensive hormonal and targeted therapy. Understanding this range is essential for evaluating your medical aid cover.
What Is Prostate Cancer?
Prostate cancer arises from the glandular cells of the prostate. It is classified by Gleason score (or Grade Group 1–5), PSA level, and clinical stage. Most prostate cancers are slow-growing; a subset are aggressive and require immediate systemic treatment.
Key classification tiers: - Low-risk / Very low-risk: Active surveillance; no immediate treatment. - Intermediate-risk: Radiation or radical prostatectomy. - High-risk / Locally advanced: Radiation + androgen deprivation therapy (ADT). - Metastatic castration-sensitive (mCSPC): ADT ± docetaxel or novel hormonal agents. - Metastatic castration-resistant (mCRPC): ADT + abiraterone, enzalutamide, or other second-line agents.
PMB Coverage in South Africa
Prostate cancer is covered under the Prescribed Minimum Benefits (PMB) as a Level 1 oncological condition. This means:
- Your medical aid cannot refuse to cover prostate cancer treatment.
- The PMB minimum treatment standard for localised disease is radical prostatectomy or radiation therapy.
- For metastatic disease, ADT (androgen deprivation therapy) is the PMB minimum standard.
- Novel hormonal agents (abiraterone, enzalutamide) are generally NOT considered the PMB minimum treatment standard and require exceptional-needs authorisation.
Prostate cancer is NOT a Chronic Disease List (CDL) condition. There is no CDL benefit to register for. Cover is entirely through the PMB oncology framework.
PSA Screening: Not a PMB Benefit
This is an important and frequently misunderstood point. PSA (Prostate Specific Antigen) screening for asymptomatic men is NOT a Prescribed Minimum Benefit. Medical aids are not legally obligated to fund PSA tests. Screening coverage varies widely:
- Some comprehensive plans cover annual PSA tests after age 45 or 50.
- Many hospital and mid-tier plans do not cover preventive screening at all.
- If your PSA screen is not covered, you pay out of pocket (typically R200–R600 per test).
Active surveillance for diagnosed low-risk disease involves regular PSA tests, digital rectal examinations, and periodic biopsy — the cumulative cost can reach R15,000–R25,000 per year without treatment.
Treatment Pathway
Active surveillance (low-risk): No active treatment. PSA every 3–6 months, periodic MRI and biopsy. Shift to treatment if progression detected.
Radical prostatectomy (localised): Surgical removal of the prostate. Open, laparoscopic, or robotic-assisted. Robotic-assisted prostatectomy (da Vinci system) is not universally funded; some schemes classify it as non-PMB or fund only open/laparoscopic techniques. Specialist shortfall on prostatectomy is significant.
Radiation therapy (localised/locally advanced): External beam radiation therapy (EBRT) or brachytherapy. Typically funded under PMB.
Androgen deprivation therapy (ADT): GnRH agonists (leuprolide, triptorelin) — monthly or quarterly depot injections. Monthly cost approximately R2,500–R3,000. This is the PMB-funded systemic treatment standard.
Novel hormonal agents (mCRPC): Abiraterone (Zytiga) blocks androgen synthesis; monthly cost approximately R10,000–R15,000. Enzalutamide (Xtandi) blocks androgen receptor signalling; monthly cost approximately R18,000–R22,000. Both typically require exceptional-needs authorisation.
Medication Costs
Costs are estimated; SAHPRA SEP verification pending.
| Medication | Class | Estimated Monthly Cost |
|---|---|---|
| Leuprolide (Lucrin) | GnRH agonist | R2,500–R3,000 |
| Triptorelin (Decapeptyl) | GnRH agonist | R2,200–R2,800 |
| Bicalutamide | Anti-androgen | R700–R900 |
| Abiraterone (Zytiga) | CYP17 inhibitor | R10,000–R15,000 |
| Enzalutamide (Xtandi) | AR inhibitor | R18,000–R22,000 |
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Active surveillance only | R15,000 – R30,000 |
| Radical prostatectomy or radiation (no ADT) | R80,000 – R160,000 |
| ADT (GnRH agonist, 2 years) | R30,000 – R40,000/year |
| ADT + abiraterone (mCRPC) | R150,000 – R200,000/year |
| ADT + enzalutamide (mCRPC) | R220,000 – R300,000/year |
The Oncology Sub-Limit: Key Consideration
As with all cancers, the oncology sub-limit on your plan is the most important number. For low-risk prostate cancer under active surveillance, this is less critical — monitoring costs are modest. For metastatic disease requiring abiraterone or enzalutamide, an annual drug cost of R150,000–R250,000 makes the sub-limit directly relevant.
If your disease progresses from localised to metastatic, your treatment cost profile changes dramatically. This is an important planning consideration — especially for men in their 50s and 60s on hospital plans with low oncology sub-limits.
Gap Cover and Specialist Shortfalls
Urology specialist: Consultations and cystoscopy procedures are frequently billed above medical aid tariff.
Radiation oncologist: EBRT treatments over 4–8 weeks generate multiple shortfall events.
Anaesthesiologist: At prostatectomy.
Robotic surgery premium: If robotic-assisted prostatectomy is performed and the scheme funds only the open equivalent, the entire premium for robotic technique is patient-funded.
The gap cover OPL (~R220,000/year) is typically sufficient for active surveillance or surgery-phase shortfalls. It becomes more limiting if the disease is metastatic and the patient is simultaneously managing chemotherapy and novel hormonal agent shortfalls.
What Medical Aids Must Cover vs. What They Often Fund in Practice
| Item | PMB Status | Notes |
|---|---|---|
| PSA screening (asymptomatic) | NOT PMB | Patient cost; varies by plan |
| Diagnosis after positive screen | Yes | PMB from point of diagnosis |
| Radical prostatectomy | Yes | At DSP rates |
| Radiation therapy | Yes | PMB minimum standard |
| ADT (GnRH agonist) | Yes | PMB minimum standard |
| Abiraterone | Usually exceptional-needs | Not PMB minimum standard in most interpretations |
| Enzalutamide | Usually exceptional-needs | Not PMB minimum standard |
| Robotic prostatectomy premium | Varies | Some schemes fund; others do not |
Talk to Eldon
See which plans pay for prostate cancer cover →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).